New Insights in Hematologic Malignancies: From Pathophysiologic Mechanisms to Therapeutic Strategies

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 683

Special Issue Editor

Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen 518107, China
Interests: hematopoietic malignancies; protein phosphorylation; small molecule targeted drugs; rare blood disorders

Special Issue Information

Dear Colleagues,

This Special Issue will focus on the pathogenesis, diagnosis, prognosis, and treatment of hematologic malignancies, including but not limited to leukemia, lymphoma, and myeloma. Hematologic malignancies are a diverse group of disorders arising from the abnormal proliferation and differentiation of hematopoietic cells, often driven by complex genetic, epigenetic, and microenvironmental factors. While targeted therapies and immunotherapies have improved outcomes for some patients, resistance and relapse continue to pose major challenges, emphasizing the urgency of uncovering fundamental disease mechanisms and identifying new therapeutic targets.

This Special Issue will also consider studies on emerging disease models, including organoids, 3D cultures, and patient-derived xenografts, which can help recreate the tumor microenvironment and support precision medicine. Contributions addressing novel diagnostic biomarkers, resistance mechanisms, immune evasion, treatment-related complications, and translational strategies are highly encouraged. Research exploring the interactions between malignant cells and the bone marrow or lymphoid niche, as well as the impact of systemic inflammation, immune dysregulation, and disease-associated comorbidities, will also be included.

Overall, this Special Issue aims to bring together recent insights into the biological and clinical management of hematologic malignancies, fostering interdisciplinary collaboration and facilitating translational advancements toward optimized precision medicine.

Dr. Yun Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • leukemia
  • hematological malignancies
  • tumor microenvironment
  • disease models
  • precision medicine
  • immunotherapy
  • targeted therapy
  • drug resistance
  • biomarkers
  • translational research

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

29 pages, 1395 KiB  
Review
Advances and Challenges in Targeted Therapy and Its Combination Strategies for Leukemia
by Zhiyuan Zhong, Ran Yao, Yifei Duan, Cheng Ouyang, Zefan Du, Lindi Li, Hailin Zou, Yong Liu, Hongman Xue, Liang Li and Chun Chen
Biomedicines 2025, 13(7), 1652; https://doi.org/10.3390/biomedicines13071652 - 7 Jul 2025
Viewed by 508
Abstract
Leukemia is a group of hematological malignancies with a complex pathogenesis and diverse clinical manifestations. Although traditional treatments such as chemotherapy, radiotherapy, and hematopoietic stem cell transplantation have improved patient outcomes, their efficacy is often limited by non-specificity, drug resistance, and relapse. In [...] Read more.
Leukemia is a group of hematological malignancies with a complex pathogenesis and diverse clinical manifestations. Although traditional treatments such as chemotherapy, radiotherapy, and hematopoietic stem cell transplantation have improved patient outcomes, their efficacy is often limited by non-specificity, drug resistance, and relapse. In recent years, targeted therapy has emerged as a major breakthrough, offering new opportunities for precision medicine in leukemia. The development of molecularly targeted agents has significantly advanced our ability to treat specific leukemia subtypes. However, challenges such as resistance to targeted drugs, adverse effects, and tumor heterogeneity remain significant obstacles. As a result, treatment strategies are shifting from single-agent chemotherapy toward combination therapies that integrate targeted agents, aiming to enhance therapeutic efficacy and reduce the likelihood of resistance. This review summarizes the current research landscape, clinical applications, and limitations of targeted therapies in leukemia, with a focus on recent progress in combination treatment strategies and ongoing clinical trials. Full article
Show Figures

Figure 1

Back to TopTop